欧洲指南:肥胖患者围术期静脉血栓栓塞预防
该指南针对肥胖患者(包括减重手术和非减重手术)的围术期静脉血栓栓塞预防进行系统文献检索与分析,按血栓风险分层和预防方式(机械、药物、下腔静脉滤器)评估。低风险肥胖患者可用低剂量低分子肝素(3000-4000 anti-Xa IU 每12小时皮下),高风险患者建议更高剂量(4000-6000 anti-Xa IU 每12小时皮下),出院后高风险患者可延长预防10-15天。缺乏高质量随机试验,无法给出强推荐。
要点
- 低血栓风险肥胖患者可用低剂量低分子肝素3000-4000 anti-Xa IU每12小时皮下。
- 高血栓风险肥胖患者建议低分子肝素4000-6000 anti-Xa IU每12小时皮下。
- 高血栓风险肥胖患者出院后可延长预防10-15天,耐受性良好。
核心结论
- 低风险肥胖患者低剂量低分子肝素可接受,高风险患者应使用更高剂量。
- 高血栓风险肥胖患者出院后延长预防10-15天耐受性良好。
- 缺乏低偏倚风险的高质量随机试验,无法提出强推荐。
研究设计与样本
- 系统文献检索,纳入肥胖患者(减重手术或非减重手术)。
- 按静脉血栓栓塞低风险和高风险分层(年龄>55岁、BMI>55 kg/m²、静脉血栓栓塞史、静脉疾病、睡眠呼吸暂停、高凝状态或肺动脉高压)。
- 分析预防方式包括下肢压迫装置、药物预防或下腔静脉滤器。
主要发现
- 两项前瞻性研究比较机械装置联合药物预防与单用机械装置,无显著差异。
- 少数随机对照研究和多数前瞻性非随机研究表明低剂量低分子肝素(3000-4000 anti-Xa IU 每12小时皮下)对低风险肥胖患者可接受。
- 高风险肥胖患者建议更高剂量低分子肝素(4000-6000 anti-Xa IU 每12小时皮下)。
- 下腔静脉滤器在减重手术患者中的安全性和有效性高度异质。
- 无随机试验分析非减重手术肥胖患者的静脉血栓栓塞预防。
关键数值与推荐
- 低风险肥胖患者:低分子肝素3000-4000 anti-Xa IU 每12小时皮下。
- 高风险肥胖患者:低分子肝素4000-6000 anti-Xa IU 每12小时皮下。
- 高血栓风险肥胖患者出院后延长预防10-15天。
- BMI>40 kg/m²的肥胖患者可考虑更高剂量抗凝药。
临床怎么用
- 根据血栓风险分层选择低分子肝素剂量:低风险3000-4000 anti-Xa IU 每12小时皮下,高风险4000-6000 anti-Xa IU 每12小时皮下。
- 高血栓风险肥胖患者出院后延长预防10-15天。
- BMI>40 kg/m²可考虑更高剂量抗凝药。
局限性
- 缺乏低偏倚风险的高质量随机试验,无法提出强推荐。
- 无随机试验分析非减重手术肥胖患者的静脉血栓栓塞预防。
- 下腔静脉滤器在减重手术患者中的安全性和有效性高度异质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
: A systematic literature search was performed and patients were selected as obese patients undergoing bariatric surgery or obese patients undergoing nonbariatric surgical procedures. In addition, patients were stratified according to low risk of venous thromboembolism and high risk of venous thromboembolism (age >55 years, BMI >55 kg m, history of venous thromboembolism, venous disease, sleep apnoea, hypercoagulability or pulmonary hypertension). Prophylaxis of venous thromboembolism was analysed depending on the type of modality: compression devices of the lower extremities (including intermittent pneumatic compression and graduated compression stockings), pharmacological prophylaxis or inferior vena cava filters. Two prospective studies compared mechanical devices and pharmacological prophylaxis vs. a mechanical device alone without significant differences. A few randomised controlled studies and most of the prospective nonrandomised studies showed that low-dose low molecular weight heparin (3000 to 4000 anti-Xa IU 12 h subcutaneously) was acceptable for obese patients with a lower risk of venous thromboembolism, but a higher dose of low molecular weight heparin (4000 to 6000 anti-Xa IU 12 h subcutaneously) should be proposed for obese patients with a higher risk of venous thromboembolism. Extended prophylaxis for 10 to 15 days was well tolerated for obese patients with a high risk of venous thromboembolism in the postdischarge period. The safety and efficacy of inferior vena cava filters in bariatric surgical patients is highly heterogeneous. There were no randomised trials that analysed prophylaxis of venous thromboembolism in obese patients undergoing nonbariatric surgery. Higher doses of anticoagulants could be proposed for obese patients with a BMI more than 40 kg m. The lack of good quality randomised trials with a low risk of bias did not allow us to propose strong recommendations.
引用
- Venclauskas L, Maleckas A, Arcelus JI, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the obese patient. Eur J Anaesthesiol. 2018. PMID: 29112546. doi:10.1097/EJA.0000000000000703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。